Holen Sie sich die Stockscreener-App
10.49
5.92%
-0.66
Polyrizon Ltd Aktie (PLRZ) Neueste Nachrichten
Polyrizon announces closing of registered direct offering - Medical Buyer
Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement - TipRanks
Single investor funds new Polyrizon (PLRZ) cash raise - Stock Titan
Polyrizon Ltd. (PLRZ) Stock: Company Closes $4 Million Deal With Institutional Investor - Blockonomi
Polyrizon Ltd. Closes $4 Million Registered Direct Offering and Concurrent Private Placement - quiverquant.com
One investor puts about $4 million into Polyrizon - Stock Titan
$4M funding deal gives Polyrizon (PLRZ) investor long-term warrant rights - Stock Titan
Polyrizon raises $4 million in registered direct offering - Investing.com
One investor agreed to buy Polyrizon shares and warrants; proceeds are expected at about $4 million. - Stock Titan
Polyrizon Tumbles on Clinical Studies - Baystreet.ca
Polyrizon completes contracting for allergy blocker trial sites - Investing.com
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study - FinancialContent
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon (PLRZ) Latest: Closes 6.26% Lower at $10.49 in the Current Update; Range Check: Support at $9.97 and Resistance at $11.01 Frame the Range in Latest TradingWyckoff Accumulation - vinanet.vn
Polyrizon Finalizes U.S. Clinical Site Network for NASARIX Allergy Study - TipRanks
Polyrizon (PLRZ) lines up sites for 120-patient allergy study - Stock Titan
Polyrizon completes contracting with all five clinical sites By Investing.com - Investing.com South Africa
Polyrizon Completes Site Contracting for NASARIX™ Seasonal Allergic Rhinitis Study - Quiver Quantitative
Polyrizon's planned allergy study will compare its spray with saline in up to 120 patients - Stock Titan
Polyrizon completes contracting with all five clinical sites - Investing.com
Polyrizon (PLRZ) Close and Levels: Records a 5.65% Decrease to $10.36 for the Current Session; Nearby Levels: the Current Price Sits Inside the Supplied Technical Range in the Available RecordRectangle Pattern - vinanet.vn
Polyrizon Ltd. (PLRZ) Gains 2.14% to $10.98, Holding Support Amid Biotech InterestTPO Profile - vinanet.vn
Polyrizon Ltd. (PLRZ): MMCAP group discloses 9.6% beneficial stake - Stock Titan
DISCLOSED: Insiders Are Now Buying *This Stock* Sootoday.com (Je9ZHM0WVP) - Mshale
Polyrizon Ltd (PLRZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polyrizon Ltd. (PLRZ) Slips 2.24% as Shares Test Key Support Zone Near $10.76Volume Gap - vinanet.vn
PLRZ.O PE Ratio & Valuation, Is PLRZ.O Overvalued - Intellectia AI
Polyrizon Ltd (PLRZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Polyrizon Ltd (PLRZ) Institutional Confidence - TradingKey
Polyrizon Ltd (PLRZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Polyrizon Ltd (PLRZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Polyrizon Ltd (PLRZ) Cash Flow - TradingKey
Polyrizon Ltd (PLRZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Polyrizon Ltd (PLRZ) Balance Sheet - TradingKey
TradingKey - TradingKey
Polyrizon Ltd (PLRZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Polyrizon Ltd. Revenue Breakdown – NASDAQ:PLRZ - TradingView
PLRZ|Polyrizon Ltd|Price:13.800|Chg%:-0.880 - TradingKey
Polyrizon (PLRZ) Advances 3.23% as Stock Tests Key Resistance Near $14.09Volume Nodes - dars.gov.et
Polyrizon (PLRZ) Slips Slightly as Stock Hovers Near Support LevelsDescending Triangle - dars.gov.et
Polyrizon Shareholders Approve New Executive Compensation Policy on July 13, 2026 - TipRanks
Polyrizon (PLRZ) locks in 3-year executive and director pay policy - Stock Titan
Polyrizon Ltd. (PLRZ) Rises 2.09% as Shares Approach Resistance at $15.38Buyback Factor - dars.gov.et
Polyrizon Ltd. (PLRZ) Rallies 7.32% to $15.40 — Bulls Test Key ResistanceDouble Top - DonanımHaber
Polyrizon (PLRZ) Holds Steady Near Support as Stock Edges HigherOption Strike Build - dars.gov.et
Polyrizon retains Nasdaq listing following hearings panel - MSN
Polyrizon Clears Key Safety Milestone for NASARIX Allergy Nasal Spray - TipRanks
Polyrizon (PLRZ) clears NASARIX biocompatibility milestone toward first human trial - Stock Titan
Polyrizon Advances on Test Results - Baystreet.ca
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ) - Yahoo Finance
Polyrizon completes biocompatibility tests for allergy nasal spray - Investing.com
Polyrizon stock rises on biocompatibility test results By Investing.com - Investing.com Nigeria
Polyrizon completes biocompatibility tests for allergy nasal spray By Investing.com - Investing.com Canada
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial - The Manila Times
Polyrizon Announces Successful Biocompatibility Results for NASARIX Allergy Blocker Nasal Spray - Quiver Quantitative
Polyrizon’s allergy nasal spray clears safety tests, advancing human trial plans - Stock Titan
0.69%
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):